共 19 条
[1]
Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Wang H,Cheng F,Cuenca A,et al. Blood . 2005
[2]
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. O’Brien,SG,Guilhot,F,Larson,R A. The New England Journal of Medicine . 2003
[3]
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. Hughes TP,Kaeda J,Branford S,et al. The New England Journal of Medicine . 2003
[4]
Imatinib induceshematologic and cytogenetic responses in patients with chronicmyeloid leukemia in myeloid blast crisis:Results of a phaseⅡstudy〔J〕. Sawyers CL,Hochhaus A,Feldman E,et al. Blood . 2002
[5]
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Ottmann,O. G.,Druker,B. J.,Sawyers,C. L.,Goldman,J. M.,Reiffers,J.,Silver,R. T.,Tura,S.,Fischer,T.,Deininger,M. W.,Schiffer,C. A.,Baccarani,M.,Gratwohl,A.,Hochhaus,A.,Hoelzer,D.,Fernandes-Reese,S.,Gathmann,I.,Capdeville,R.,O’Brien,S. G. Blood . 2002
[6]
Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood. Grewal S S,Barker J N,Davies S M et al. Blood . 2003
[7]
Peripheral blood stem cell verus bone marrow allotransplantation: does the source of hematopoietic stem cells mater. Korbling M,AnderliniP. Blood . 2001
[8]
Karyotypic analysispredicts outcome of preremission and postremission therapy in adultacute myeloid leukemia:a Southwest Oncology Group/Eastern Coop-erative Oncology Group Study. Slovak ML,Kopecky KJ,Cassileth PA,et al. Blood . 2000
[9]
Mecheoisms of transformation by the bcr-abl on cogene:new perspectives in the post-imatinib era. Van Etten RA. Leukemia Research . 2004
[10]
Chronic myelogenous leu kemia. Druker BJ,Sawyers cl,Capdevill R,et al. Hematology . 2001